ReviewCells2023
Mesenchymal Stem/Stromal Cells for Therapeutic Angiogenesis.
Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Outcomes of autologous bone marrow mononuclear cell administration combined with educational intervention in the treatment of autism spectrum disorder: a randomized, open-label, controlled phase II clinical trial.Stem cell research & therapy · 2025Trial
- 3D bioprinted human vascular organoid sheets promote functional ischemic repair and exhibit adaptive in vivo remodeling.BMC medicine · 2026Article
- Tuning scaffold degradation with non-natural peptidomimetics to control human umbilical vein endothelial cell morphology and vessel formation.Acta biomaterialia · 2026Article
- Mechanical stretch loading of BMSCs-PLCL composite scaffolds accelerate diabetic wound healing by protecting endothelial cells and promoting angiogenesis.Stem cell research & therapy · 2026Article
- Coupling intraoperative bioprinting and surgical micropuncture for synergistic scaffold vascularization.Biomaterials · 2026Article
- Foam Cells: The Origin of Formation and Target for Plant-derived Bioactive Compounds.Current medicinal chemistry · 2026Review
- Cx43 hemichannel-mediated paracrine involves in the promotion of MSCs on skin wound healing.Stem cell research & therapy · 2025Article
- Tuning Scaffold Degradation with Non-Natural Peptidomimetics to Control Human Umbilical Vein Endothelial Cell Morphology and Vessel Formation.bioRxiv : the preprint server for biology · 2025Article
- Myocardial infarction induces endothelial dysfunction with independence of cardiovascular risk factors.Angiogenesis · 2025Article
- Decellularized Porcine Aorta as a Scaffold for Human Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells in Tissue Engineering.Stem cell reviews and reports · 2025Article
- Review
- The Outcome of Cell Therapy Treating Urinary Incontinence Correlates with Precise Cell Localization in the Sphincter Complex.Biomedicines · 2025Article
- Investigational New Drug-enabling studies to use genetically modified mesenchymal stromal cells in patients with critical limb ischemia.Stem cells translational medicine · 2025Article
- DMP1-mediated transformation of DPSCs to CD31Frontiers in cell and developmental biology · 2025Article
- Mesenchymal Stem Cell-Derived Exosomes Hold Promise in the Treatment of Diabetic Foot Ulcers.International journal of nanomedicine · 2025Review
- Intrathecal injection of bone marrow concentrate in children with autism spectrum disorder: a retrospective chart analysis.Frontiers in medicine · 2025Article
- Mechanisms, strategies, and clinical application progress of subcutaneous transplantation angiogenesis.Frontiers in bioengineering and biotechnology · 2025Review
- Article
- The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics.MedComm · 2024Review
- Molecular mechanisms responsible for mesenchymal stem cell-dependent improvement of islet cell transplantation.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem/stromal cells (MSCs) are known to possess medicinal properties to facilitate vascular regeneration. Recent advances in the understanding of the utilities of MSCs in physiological/pathological tissue repair and technologies in isolation, expansion, and enhancement strategies have led to the use of MSCs for vascular disease-related treatments. Various conditions, including chronic arterial occlusive disease, diabetic ulcers, and chronic wounds, cause significant morbidity in patients. Therapeutic angiogenesis by cell therapy has led to the possibilities of treatment options in promoting angiogenesis, treating chronic wounds, and improving amputation-free survival. Current perspectives on the options for the use of MSCs for therapeutic angiogenesis in vascular research and in medicine, either as a monotherapy or in combination with conventional interventions, for treating patients with peripheral artery diseases are discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.